Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?

References

• Chen CD, Chen SU, Yang YS. Prevention and management of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol. 2012;26(6):1–5.
   PubMed Web of Science ®Google Scholar
• McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344(8917):235–236.
   PubMed Web of Science ®Google Scholar
• Gomez R, Simon C, Remohi J, et al. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology. 2002;143(11):4339–4348.
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147(11):5400–5411.
   PubMed Web of Science ®Google Scholar
• Nastri CO, Ferriani RA, Rocha IA, et al. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010;27(2-3):121–128.
   PubMed Web of Science ®Google Scholar
• Brannstrom M, Wang L, Norman RJ. Effects of cytokines on prostaglandin production and steroidogenesis of incubated preovulatory follicles of the rat. Biol Reprod. 1993;48(1):165–171.
   PubMed Web of Science ®Google Scholar
• Pauli SA, Tang H, Wang J, et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 2005;146(3):1301–1311.
   PubMed Web of Science ®Google Scholar
• Smith SK. Angiogenesis and reproduction. BJOG. 2001;108:777–783.
   PubMedGoogle Scholar
• Heryanto B, Lipson KE, Rogers PA. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. Reproduction. 2003;125(3):337–346.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153(1):13–19.
   PubMed Web of Science ®Google Scholar
• Mathur R, Kailasam C, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil (Camb). 2007;10(2):75–85.
   PubMedGoogle Scholar
• Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online. 2008;17(6):751–755.
   PubMed Web of Science ®Google Scholar
• Douglas NC, Zimmermann RC, Tan QK, et al. VEGFR-1 blockade disrupts peri-implantation decidual angiogenesis and macrophage recruitment. Vasc Cell. 2014;6:16.
   PubMedGoogle Scholar
• Alvarez C, Alonso-Muriel I, Garcia G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod. 2007;22(12):3210–3214.
   PubMed Web of Science ®Google Scholar
• Inal HA, Ozturk Inal ZH, Yilmaz N, et al. The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS. Clin Exp Obstet Gynecol. 2017;44(1):122–128.
   PubMed Web of Science ®Google Scholar
• Saylan A, Arioz DT, Koken T, et al. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand. 2010;89(5):692–699.
   PubMed Web of Science ®Google Scholar
• Ozcakir HT, Giray SG, Ozbilgin MK, et al. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary. Acta Obstet Gynecol Scand. 2005;84(9):887–893.
   PubMed Web of Science ®Google Scholar
• Kasap E, Turan GA, Eskicioğlu F, et al. Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model. Gynecol Endocrinol. 2016;32(8):634–640.
   PubMed Web of Science ®Google Scholar
• Ferrero H, Garcia-Pascual CM, Gaytan M, et al. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril. 2014;102(5):1468–1476 e1.
   PubMed Web of Science ®Google Scholar
• Atilgan R, Pala S, Yavuzkir S, et al. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model? J Obstet Gynaecol. 2019;39(5):687–694.
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Electronic address AAO, Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106:1634–1647.
   PubMed Web of Science ®Google Scholar
• Leitao VM, Moroni RM, Seko LM, et al. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2014;101(3):664–675.
   PubMed Web of Science ®Google Scholar
• Tang H, Mourad S, Zhai SD, et al. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2016;11: CD008605.
   PubMedGoogle Scholar
• Hortu I, Karadadas E, Ozceltik G, et al. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Arch Gynecol Obstet. 2021;303(4):1099–1108.
   PubMed Web of Science ®Google Scholar
• Delgado-Rosas F, Gómez R, Ferrero H, et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction. 2011;142(5):745–755.
   PubMed Web of Science ®Google Scholar
• Coban PG, Oruc AS, Ozaksit MG, et al. Comparison of the efficacy of cabergoline and bromocriptine in a rat model of ovarian hyperstimulation syndrome. J Reprod Med. 2018;63:27–32.
   Web of Science ®Google Scholar